These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38843018)

  • 1. [The use of immunoglobulins and monoclonal antibodies against COVID-19].
    Popadyuk EE; Sizikova TE; Khmelev AL; Timofeev MA; Lebedev VN; Borisevich SV
    Vopr Virusol; 2024 May; 69(2):119-126. PubMed ID: 38843018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of monoclonal antibodies in COVID-19: Role in immunotherapy, vaccine development and viral detection.
    Tabll AA; Shahein YE; Omran MM; Elnakib MM; Ragheb AA; Amer KE
    Hum Antibodies; 2021; 29(3):179-191. PubMed ID: 33998533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing monoclonal antibodies for treatment of COVID-19.
    Taylor PC; Adams AC; Hufford MM; de la Torre I; Winthrop K; Gottlieb RL
    Nat Rev Immunol; 2021 Jun; 21(6):382-393. PubMed ID: 33875867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspective on the Role of Antibodies and Potential Therapeutic Drugs to Combat COVID-19.
    Tandon S; Aggarwal A; Jain S; Shukla S; Chaudhary S
    Protein J; 2020 Dec; 39(6):631-643. PubMed ID: 33034824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.
    Somasundaram R; Choraria A; Antonysamy M
    Int Immunopharmacol; 2020 Aug; 85():106654. PubMed ID: 32512271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
    Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
    BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential therapeutic options for COVID-19: an update on current evidence.
    Niknam Z; Jafari A; Golchin A; Danesh Pouya F; Nemati M; Rezaei-Tavirani M; Rasmi Y
    Eur J Med Res; 2022 Jan; 27(1):6. PubMed ID: 35027080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Passive immune therapies: another tool against COVID-19.
    Estcourt LJ
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):628-641. PubMed ID: 34889410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convalescent plasma - Is it useful for treating SARS Co-V2 infection?
    Ranganathan S; Iyer RN
    Indian J Med Microbiol; 2020; 38(3 & 4):252-260. PubMed ID: 33154232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.
    Zimmerli A; Monti M; Fenwick C; Eckerle I; Beigelman-Aubry C; Pellaton C; Jaton K; Dumas D; Stamm GM; Infanti L; Andreu-Ullrich H; Germann D; Mean M; Vollenweider P; Stadelmann R; Prella M; Comte D; Guery B; Gachoud D; Rufer N
    Front Immunol; 2021; 12():613502. PubMed ID: 33968017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of neutralizing antibodies against SARS-CoV-2 and their common features.
    Liu LD; Lian C; Yeap LS; Meng FL
    J Mol Cell Biol; 2020 Nov; 12(12):980-986. PubMed ID: 33377928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis.
    Siemieniuk RA; Bartoszko JJ; Díaz Martinez JP; Kum E; Qasim A; Zeraatkar D; Izcovich A; Mangala S; Ge L; Han MA; Agoritsas T; Arnold D; Ávila C; Chu DK; Couban R; Cusano E; Darzi AJ; Devji T; Foroutan F; Ghadimi M; Khamis A; Lamontagne F; Loeb M; Miroshnychenko A; Motaghi S; Murthy S; Mustafa RA; Rada G; Rochwerg B; Switzer C; Vandvik PO; Vernooij RW; Wang Y; Yao L; Guyatt GH; Brignardello-Petersen R
    BMJ; 2021 Sep; 374():n2231. PubMed ID: 34556486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
    Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
    J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibody: a savior in the Covid-19 disease.
    Gupta SL; Jaiswal RK
    Mol Biol Rep; 2022 Mar; 49(3):2465-2474. PubMed ID: 34988889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2.
    Sajna KV; Kamat S
    Cytotherapy; 2021 Feb; 23(2):101-110. PubMed ID: 32988772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 Updates: Monoclonal Antibodies for COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):16. PubMed ID: 35139286
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.